Isabelle Lefebvre

Chief Regulatory Officer

As Chief Regulatory Officer, Isabelle Lefebvre is responsible for EyePoint Pharmaceuticals’ regulatory strategy and compliance, with a focus on bringing innovative products to patients in the US and around the world. She oversees the Quality Management organization. Ms. Lefebvre has over 30 years of global regulatory affairs and compliance experience across all phases of drug development, including ophthalmic and ocular conditions. Prior to joining EyePoint in 2022, she served as Vice President, Head of Regulatory Science, at Hengrui USA, where she oversaw US and EU regulatory strategies for clinical programs in various phases of development. Ms. Lefebvre spent 10 years at Bausch Health Companies, Inc., where she held roles of increasing responsibility and led the successful approvals of two ocular drug products, LOTEMAX gel and VYZULTA®. Earlier in her career, Ms. Lefebvre held senior roles in regulatory strategy and affairs at Lundbeck, Inc.; Alpharma Pharmaceuticals; Bristol-Myers Squibb. Ms. Lefebvre holds a B.S. in Biochemistry from the University of Montreal and an M.S. in Regulatory Affairs from Northeastern University.